Spyre Therapeutics (SYRE) Payables (2016 - 2025)
Historic Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $7.5 million.
- Spyre Therapeutics' Payables rose 4437.56% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 4437.56%. This contributed to the annual value of $666000.0 for FY2024, which is 9598.41% down from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Payables is $7.5 million, which was up 4437.56% from $3.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Payables registered a high of $20.8 million during Q2 2023, and its lowest value of $666000.0 during Q4 2024.
- For the 5-year period, Spyre Therapeutics' Payables averaged around $6.2 million, with its median value being $3.3 million (2021).
- In the last 5 years, Spyre Therapeutics' Payables soared by 234963.07% in 2023 and then plummeted by 9598.41% in 2024.
- Spyre Therapeutics' Payables (Quarter) stood at $3.3 million in 2021, then tumbled by 79.6% to $677000.0 in 2022, then surged by 2349.63% to $16.6 million in 2023, then tumbled by 95.98% to $666000.0 in 2024, then skyrocketed by 1019.67% to $7.5 million in 2025.
- Its Payables was $7.5 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.7 million in Q1 2025.